Wat is de prijs voor ProMIS Neurosciences, Inc. (PMN)

Het prijs van ProMIS Neurosciences, Inc. (PMN) is $4.40

Wat is de marktkapitalisatie voor ProMIS Neurosciences, Inc. (PMN)

Marktkapitalisatie voorProMIS Neurosciences, Inc. (PMN) is $37.78M

ProMIS Neurosciences, Inc. (PMN) Uitstaande Aandelen

Based in Toronto, Canada, ProMIS Neurosciences, Inc. focuses on developing precise medical solutions for severe neurodegenerative disorders, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company employs a unique discovery platform, which incorporates proprietary algorithms like ProMIS and Collective Coordinates, to identify novel, disease-specific targets, known as epitopes, located on the surface of misfolded proteins. The firm's primary product candidates include PMN310, a monoclonal antibody designed to combat toxic oligomers associated with Alzheimer's disease. Another candidate, PMN267, aims to target proteins such as superoxide dismutase 1 and TAR-DNA binding protein 43 relevant to ALS, as well as alpha-synuclein implicated in Parkinson's disease and Lewy body dementia. Additionally, PMN442 is a monoclonal antibody engineered to address toxic alpha-synuclein oligomers and seeding fibrils linked to MSA. Originally established in 2004, the company was known as Amorfix Life Sciences Ltd. before officially adopting the name ProMIS Neurosciences, Inc. in July 2015.

Jaar	Uitstaande aandelen	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Uitstaande aandelen

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Uitstaande aandelen	Verschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	483.58M	-	AU
Moderna, Inc. MRNA.US	396.00M	-	US
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

Uitstaande aandelen

Verschil

Land